Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation

被引:44
|
作者
Caliskan, Y. [1 ]
Besisik, S. K.
Sargin, D.
Ecder, T.
机构
[1] Istanbul Univ, Sch Med, Dept Internal Med, Div Nephrol, TR-34390 Istanbul, Turkey
[2] Istanbul Univ, Sch Med, Dept Internal Med, Div Hematol,Bone Marrow Transplantat Unit, TR-34390 Istanbul, Turkey
关键词
stem cell transplantation; renal dysfunction; sepsis; cyclosporine A;
D O I
10.1038/sj.bmt.1705412
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Renal insufficiency is a common complication early after hematopoietic stem cell transplantation ( HSCT). Renal function as measured by creatinine clearance (CrCl) was prospectively evaluated in 47 patients undergoing allogeneic (n = 22) or autologous (n = 25) HSCT during the first 100 days. Renal dysfunction was classified as follows: Grade 0 (< 25% decline in CrCl), Grade 1 (>= 25% decline in CrCl but < 2 x increase in serum creatinine), Grade 2 (>= 2 x rise in serum creatinine but no need for dialysis) and Grade 3 (>= 2 x rise in serum creatinine and need for dialysis). Thirty-three patients (70%) had Grade 1-3 renal dysfunction. Renal dysfunction was more common after myeloablative allogeneic HSCT (91%) than autologous HSCT (52%) (P = 0.004), and was associated with a high risk of mortality (P = 0.039). Sepsis in autologous HSCT patients and cyclosporine toxicity in allogeneic HSCT patients were associated with renal dysfunction. We conclude that autologous and allogeneic HSCT differ in the likelihood and causes of renal dysfunction.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 50 条
  • [41] An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation
    Lopes, J. A.
    Jorge, S.
    Silva, S.
    de Almeida, E.
    Abreu, F.
    Martins, C.
    do Carmo, J. A.
    Lacerda, J. F.
    Prata, M. M.
    BONE MARROW TRANSPLANTATION, 2006, 38 (05) : 395 - 395
  • [42] An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation
    J A Lopes
    S Jorge
    S Silva
    E de Almeida
    F Abreu
    C Martins
    J A do Carmo
    J F Lacerda
    M M Prata
    Bone Marrow Transplantation, 2006, 38 : 395 - 395
  • [43] Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation
    Nygaard, M.
    Hovgaard, D.
    Schjodt, I. M.
    Andersen, N. S.
    Vindelov, L.
    Sengelov, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (03) : 358 - 361
  • [44] Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after
    Tykodi, Scott S.
    Sandmaier, Brenda M.
    Warren, Edus H.
    Thompson, John A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (06) : 763 - 773
  • [45] Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: The role of community respiratory viruses
    Erard, Veronique
    Chien, Jason W.
    Kim, Hyung W.
    Nichols, W. Garrett
    Flowers, Mary E.
    Martin, Paul J.
    Corey, Lawrence
    Boeckh, Michael
    JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (12): : 1619 - 1625
  • [46] IMMUNE RECONSTITUTION AFTER MYELOABLATIVE AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN CHILDREN WITH BRAIN TUMORS
    Khurana, Monica
    Aguilar, Ana
    Hagar, Ward
    Torkildson, Joseph
    Walters, Mark
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S101 - S102
  • [47] Renal functions after allogeneic hematopoietic stem cell transplantation in children
    Ileri, T.
    Ertem, M.
    Ozcakar, Z. B.
    Azik, F.
    Citak, F.
    Unal, E.
    Sayili, A.
    Ekim, M.
    Uysal, Z.
    Yalcinkaya, F.
    PEDIATRIC NEPHROLOGY, 2007, 22 (09) : 1557 - 1557
  • [48] Extended Abstract: Lung Injury after Allogeneic Hematopoietic Cell Transplantation
    Palaniyandi, Senthilnathan
    Kumari, Reena
    Hildebrandt, Gerhard C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S128 - S130
  • [49] Superior long term progression free survival of myeloablative allogeneic hematopoietic stem cell transplantation for multiple myeloma compared to autologous hematopoietic stem cell transplantation after identical conditioning regimen
    Khaled, Yaser
    Kato, Koji
    Levine, John E.
    Mellacheruvu, Smitha
    Jakubowiak, Andrzej
    Krijanovski, Oleg
    Peres, Edward
    Reddy, Pavan
    Knott, Kevin
    Yanik, Greg
    Ferrara, James
    Mineishi, Shin
    BLOOD, 2007, 110 (11) : 890A - 890A
  • [50] Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?
    Kharfan-Dabaja, M. A.
    El-Jurdi, N.
    Ayala, E.
    Kanate, A. S.
    Savani, B. N.
    Hamadani, M.
    BONE MARROW TRANSPLANTATION, 2017, 52 (11) : 1487 - 1494